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NAFLD May Be a Common Underlying Liver Disease 
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The incidence of hepatocellular carcinoma (HCC) in the United States is increasing, but the 
clinical characteristics of American patients with HCC have not been well described. The 
aims of this study were to determine the etiology of liver disease and short-term outcome 
among HCC patients presenting to a single center in the United States. One hundred five 
consecutive patients with HCC were studied; mean age was 59 years, 67% were men, and 
76% were non-Hispanic white. The most common etiology of liver disease was hepatitis C 
(51%) and cryptogenic cirrhosis (29%). Half of the patients with cryptogenic cirrhosis had 
histologic or clinical features associated with nonalcoholic fatty liver disease (NAFLD). 
Fifty-three (50%) patients had HCC detected during surveillance (group I), whereas the 
remaining patients had symptomatic tumors (group 11). Group I patients had smaller tumors 
(P = . O l ) ,  were more likely to be eligible for surgical treatment (P = .005), and had a better 
median survival compared with patients in group I1 (P = .OO1). Patients with cryptogenic 
cirrhosis were less likely to have undergone HCC surveillance and had larger tumors at 
diagnosis. In conclusion, hepatitis C and cryptogenic liver disease are the most common 
etiologies of diseases in our patients with HCC. NAFLD accounted for at least 13% of the 
cases. Patients who underwent surveillance had smaller tumors and were more likely to be 
candidates for surgical or local ablative therapies. Because of the increasing incidence of 
NAFLD, further studies are needed to determine the risk of HCC in patients with NAFLD. 
(HEPATOLOGY 2002;36: 1349- 1354.) 
epatocellular carcinoma (HCC) was formerly 
considered an uncommon malignancy in the H United States. Intrahepatic liver cancer (combi- 
nation of HCC and cholangiocarcinoma) ranked as the 
8th most common malignancy in the United States from 
1973 to 1980, accounting for 1 death per 100,000.' 
However, 3 national databases (NCI Surveillance Epide- 
miology and End Results database, United States vital 
statistics, and Department of Veteran Administration) 
found that the incidence of HCC in the United States has 
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been increasing over the last decade.2 In 1998, intrahe- 
patic liver cancer ranked as the 6th most common malig- 
nancy in the United States, resulting in a death rate of 3.5 
per 100,000.' Much of the increase in intrahepatic liver 
cancer is related to an increase in the incidence of HCC. 
The increase in incidence of HCC in the United States 
has been attributed to the hepatitis C virus (HCV) epi- 
demic, but data on the prevalence of HCV infection 
among patients with HCC in the United States are not 
available. Recently, nonalcoholic fatty liver disease 
(NAFLD) has been recognized to be one of the most 
common causes of chronic liver disease in the United 
States.3 Several studies have demonstrated that NAFLD 
may progress to cirrhosis.4-6 In addition, recent studies 
found that a high percentage of patients who underwent 
liver transplantation for cryptogenic cirrhosis probably 
had NAFLD, indicating that NAFLD may be an impor- 
tant cause of end-stage liver di~ease.7.~ A study from Italy 
also reported an association between NAFLD and 
HCC.IO 
Survival of patients with HCC has improved mini- 
mally over the last 2 decades, with I-year survival rate 
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increasing from 14% in 1977 to 1981 to 23% in 1992 to 
1996, whereas the 5-year survival rate rose from 2% to 
5%. These disappointing results were observed despite 
dramatic improvements in the survival of patients with 
other malignancies such as breast or colon cancer during 
the same time period. Several prospective studies have 
found that surveillance of high-risk individuals can in- 
crease the rate of detection of early HCC.’2-’5 However, 
these studies have shown minimal or no improvement in 
overall survival. Because only 13% of patients with HCC 
are eligible for liver transplantation or surgical resection,16 
limited options for curative treatment have further damp- 
ened the enthusiasm for HCC surveillance. It is unknown 
what percentage of patients with HCC in the United 
States is detected by surveillance. 
The aims of this prospective study were to determine 
the etiology of liver disease and tumor staging at diagnosis 
among HCC patients presenting to a single referral center 
in  the United States. In addition, we determined whether 
patients whose tumor was detected via surveillance were 
more likely to be candidates for surgical therapy than 
patients presenting with clinical symptoms. The results in 
our cohort of 105 consecutive HCC patients form the 
basis of this report. 
Patients and Methods 
Patients andEtioZogy. A database of all patients with 
a diagnosis of HCC was established in January, 2000, at 
the University of Michigan Medical Center per local In- 
stitutional Review Board guidelines. Written informed 
consent was obtained from each patient. The diagnostic 
criteria of HCC was based on liver histology, and, in the 
absence of histology, an AFP >200 ng/mL with a hyper- 
vascular mass on triple-phase computerized tomography 
(CT) scan or magnetic resonance imaging (MRI). The age 
at diagnosis, gcnder, ethnicity, body mass index (BMI), 
estimated duration from diagnosis of liver disease to diag- 
nosis of HCC, Child-Turcotte-Pugh (CTP) score, serum 
a-fetoprotein (AFP), and tumor size and location were 
recorded. 
Etiology of underlying liver disease was attributed to 
HCV based on detection of hepatitis C antibody/HCV 
RNA in serum, hepatitis B (HBV) [hepatitis B surface 
antigen (HBsAg)] in serum, alcohol (daily alcohol intake 
more than 30 gmiethanol per day for more than 15 years), 
hereditary hemochromatosis (HH) (positive genetic test- 
ing or hepatic iron index > I .9), primary biliary cirrhosis 
(PBC) ( serum antimitochondrial antibody and compat- 
ible histology), primary sclerosing cholangitis (PSC) 
(beading on cholangiogram), autoimmune hepatitis 
based on the revised scoring system, and a-1 antitrypsin 
deficiency (phenotypic analysis). The etiology of liver dis- 
ease was considered to be cryptogenic if no cause was 
identified after exhaustive testing as described above. The 
presence or absence of cirrhosis was determined based on 
histologic assessment of non-neoplastic liver tissue. A di- 
agnosis of diabetes was made based on the American Di- 
abetes Associa tion criteria.” Hypercholesterolemia was 
defined as a serum cholesterol of >2OO mg/dL and hyper- 
triglyceridemia as serum triglyceride level of >200 mg/ 
dL.’O Portal hypertension was defined as evidence of 
hypersplenism, history of esophagogastic varices, pres- 
ence of ascites, or hepatic encephalopathy. 
Surveillance. Patients with a diagnosis of HCC were 
divided into .2 groups for analysis. Group I (n = 53) 
patients had detection of HCC during surveillance. Sur- 
veillance included ultrasound of the liver and AFP testing 
every 6 to 12 months over a period of at least 12 months 
prior to diagnosis of HCC. In our institution, all patients 
with cirrhosis, regardless of the etiology of liver disease, 
undergo surveillance with ultrasound of the liver and AFP 
every 6 to 12 months. Eleven patients underwent tumor 
surveillance at other institutions and were referred to us 
after HCC was diagnosed. Patients with AFP levels >20 
nglmL or a solid liver mass on ultrasound were further 
evaluated by triple-phase CT or dynamic contrast-en- 
hanced MRI. Group I1 (n = 52) patients presented with 
clinical symptoms of abdominal pain, discomfort, nausea, 
or weight loss that led to evaluation and diagnosis of 
HCC. 
Treatment Strategies. All patients were assessed for 
possible liver transplantation or surgical resection. Trans- 
plant eligibility was defined as a single tumor lesion < 5  
cm in maximal diameter or 3 lesions each < 3  cm in max- 
imal diameter without portal vein infiltration or extrahe- 
patic metastasis.lX Surgical resection eligibility was 
defined as a single tumor lesion involving I hepatic lobe 
without portal vein infiltration or extrahepatic metastasis 
and Child class A. Percutaneous radio frequency thermal 
ablation of HCC is the preferred local ablative therapy in 
our center. 
Statistical Analysis. Data were analyzed with Stu- 
dent’s t test for comparison of means and x2 test with 
Yate’s correction and Fisher exact test for categorical vari- 
ables using SAS (Cary, NC). Pvalues < .05 were consid- 
ered statistically significant. 
Results 
A total of 163 patients with liver masses and liver dis- 
ease were seen in the Liver Clinic at the University of 
Michigan over a 24-month period. Of these, 105 (64%) 
patients were diagnosed with HCC.  The diagnoses in the 
remaining 58 patients included 16 dysplastic nodules, 14 
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hemangiomas, 3 cholangiocarcinomas, 9 hepatic cysts, 5 
adenomas, 5 focal nodular hyperplasia, and 6 metastatic 
liver masses. The diagnosis of HCC was made based on 
histology in 76 (72%) patients and a combination ofAFP 
and imaging in the other 29 (28%) patients. Table 1 
summarizes the demographic and clinical data of these 
105 patients. All 105 patients had chronic liver disease, 
90% had biopsy specimen-proven or clinical suspicion of 
cirrhosis. Overall, 31% of patients had AFP levels <20 
ng/mL, and only 35% had AFP levels >200 ng/mL at 
diagnosis. There was no relationship between AFP levels 
and etiologies of underlying liver disease (P  = .563). 
Of the 105 patients with HCC, 62 (59%) received 
treatment. Of  these, 11 (10%) underwent orthotopic 
liver transplantation, whereas 5 (4%) patients underwent 
surgical resection of the tumor. Twenty-two (2  1 Yo) pa- 
tients underwent percutaneous radio frequency thermal 
ablation, 1 1 (1 0%) received systemic chemotherapy, 12 
(1 1 Yo) received experimental antiangiogenesis therapy, 
and 1 received transarterial chemoembolization as the pri- 
mary method of treatment. A total of 33 (31%) patients 
died during a mean follow-up of 12.4 months (range 1 to 
25 months). 
Hepatitis C was the leading etiology of underlying liver 
disease among the patients with HCC (51%). Crypto- 
genic liver disease was the second most common diagnosis 
(29%). Compared with patients with other causes of liver 
disease, patients with cryptogenic disease were more likely 
to be women (60% vs. 28%, P = .001) and to have 
BMI 2 30 (58% vs. 25%, P .02) (Table 2). Six (20%) 
patients in the cryptogenic liver disease group had evi- 
dence of nonalcoholic steatohepatitis (NASH), and all 6 
had steatosis, lobular inflammation, ballooning degener- 
ation, and sinusoidal fibrosis'' on liver biopsy 4.3 _f 1.6 
years prior to the diagnosis of HCC. All biopsy specimens 
were reviewed by a single pathologist in our institution 
who was unaware that these patients subsequently devel- 
oped HCC. Eight additional patients had clinical features 
commonly associated with NAFLD, including a BMI 1 
30, history of diabetes mellitus, hypertriglyceridemia, and 
female gender."*O Of the 14 patients with prior histologic 
diagnosis of NASH or clinically suspected NAFLD, all 
had cirrhosis in the adjacent non-neoplastic liver at the 
time of HCC diagnosis, with only 3 having more than 
30% steatosis in the nonneoplastic liver tissue. Patients 
suspected of having NAFLD were significantly more 
obese (BMI 2 30 in 93% vs. 12.5%, P < .001), diabetic 
(93% vs. 25%, P < .OOl), and hyperlipidemic (29% vs. 
6%, P < .001) than the other patients with cryptogenic 
cirrhosis. There was no significant difference in gender, 
tumor size, and percentage with HCC surveillance be- 
tween these 2 groups. Patients with cryptogenic cirrhosis 
as the underlying liver disease were less likely to have 
undergone HCC surveillance (23% vs. 61%, P = .01). 
This resulted in larger tumors at diagnosis (7.6 vs. 4.4 cm, 
P = .03), and a lower proportion of patients eligible for 
surgical (3 underwent resection, 1 placed on transplant 
waiting list) or local ablation therapy (5 had radio fre- 
Table 2. Comparison of HCC Patients With Cryptogenic 
Cirrhosis Versus Other Etiologies 
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Table 3. Characteristics of HCC Patients Detected by 
Surveillance (Group I) and Those With Clinical Symptoms 
(Group H) 
<20 ng/mL at diagnosis, compared with 19% in the 
group I1 patients (P = .001). 
Patients whose tumors were detected by surveillance 
were more likelv to be candidates for surgical or local Group I Group II u 
Surveillance Symptomatic P 
= 53) (, = 52) Value ablative therapy. Twenty (35%) group I patients were 
eligible for liver transplantation or surgical resection, 
compared with only 5 (10%) group I1 patients (P = 
.001). Ofthese, 12 patients in group I underwent surgical 
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therapy (10 liver transplantations and 2 resections), com- 
pared with 4 in group I1 (1 transplantation and 3 resec- 
tions) (P = .01). Eighteen (34%) group I versus 6 (12%) 
group I1 patients underwent local therapy with radio fre- 
quency ablation (P = .01). Compared with group 11, 
group I patients had a significantly improved median sur- 
vival (19 vs. 5 months, P = .001). 
Discussion 
In this case series of 105 consecutive patients with 
HCC presenting to a tertiary center in the United States, 
we confirmed that H C V  is the most common underlying 
liver disease. Nevertheless, HCV only accounted for 51% 
of our cases, with cryptogenic liver disease accounting for 
29% of cases. Compared with patients with other causes 
of liver disease, patients with cryptogenic cirrhosis and 
HCC were more often women and obese. Approximately 
50% of the patients with cryptogenic liver disease had a 
prior histologic diagnosis of NASH or clinical features 
associated with NAFLD. Our  data suggest that the un- 
derlying liver disease in 13% of our patients with HCC 
may be due to 'NAFLD. Progression from NASH to HCC 
has been reported in 1 female patient after I0  years of 
follow-up.2' In a recent series from Italy, 23/641 (4%) of 
patients with IHCC were thought to have NAFLD as the 
cause of their liver disease.'O Because steatosis may de- 
crease as NAFLD progresses and not all patients with 
NAFLD are women, obese, diabetic, or hyperlipidemic, 
65 .15 the proportion of patients with NAFLD as the underlying 
NOTE. Data Dresented as mean Z standard deviation. 
quency ablation). During follow-up, 1 1 (37%) patients 
with cryptogenic liver disease died. 
There was no difference in age, gender, ethnicity, and 
Child class between group I and I1 patients (Table 3). 
Compared with patients who had symptomatic HCC 
(group 11), surveillance patients (group I) had smaller tu- 
mors at diagnosis, with a mean maximal diameter of 
3.7 t 2.1 cmvs.7.6 2 4.9cm (P= .01). However, there 
was no difference in the number of tumor nodules, pres- 
ence of portal vein invasion, and distant metastasis. Al- 
most half, 42%, of the group I patients had AFP levels 
- -  - 
liver disease among our HCC patients may even be 
higher.5,6-22 In view of the increasing prevalence of 
NAFLD in the United States, larger prospective studies 
are necessary to confirm the etiologic association between 
NAFLD and HCC. Our observation has 2 important 
implications. First, the incidence of HCC in the United 
States may continue to increase even after the conse- 
quences of the H C V  epidemic have leveled off. Second, 
and more importantly, we found that patients with cryp- 
togenic liver disease were less likely to be enrolled in HCC 
surveillance programs resulting in delay in diagnosis. This 
may be due to an underappreciation of the risk of HCC in 
these patients, compared with patients with viral 
he pa ti ti^.^^,^* 
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Our data have several limitations. Although our find- 
ings suggest that NAFLD is a common cause of the un- 
derlying liver disease in our patients with HCC, a 
prospective study of patients with NASH is necessary to 
confirm the etiologic association and to determine the risk 
of developing HCC in this population. Another limita- 
tion is that our data may not be representative of other 
regions in the United States. Michigan has a high preva- 
lence of obesity; 53% of the residents have BMI > 30. 
Despite these limitations, we believe that NAFLD may be 
an important cause of cryptogenic cirrhosis as well as 
HCC in the United States. 
Fifty percent of our patients had their tumors detected 
during surveillance. Patients who underwent surveillance 
had smaller tumors at diagnosis and were more likely to be 
eligible for surgical or local ablative therapies. In addition, 
there was a significant improvement in survival among 
those who underwent tumor surveillance. Our data sup- 
port previous findings that surveillance of patients with 
cirrhosis using AFP and ultrasound can lead to early di- 
agnosis of HCC.'3-'5,25 We recognize that the 2 groups of 
patients were not randomized, and improved survival in 
group I patients may be related to lead-time bias. Never- 
theless, our data corroborate previous studies indicating 
that surveillance may increase the rate of early detection 
and eligibility for curative therapies, which may in turn 
translate into improved survival. 
Although the patients who underwent surveillance had 
smaller tumors, half of them had more than I tumor, and 
a third had portal vein invasion at diagnosis. The high 
proportion of patients with advanced tumors despite sur- 
veillance may be related to the heterogeneity in frequency 
of surveillance (every 6-12 months) performed by a di- 
verse group of hepatologists. Even though HCC surveil- 
lance is usually performed at 6-month intervals, prior 
prospective studies have used varying intervals from 6 to 
12 months.26 We have recently implemented a stricter 
HCC surveillance program to determine whether we can 
improve our early detection rate. O u t  disappointing re- 
sults with surveillance may also be related to the insensi- 
tivity ofAFP in the early detection of HCC. Thus, 42% of 
group I patients had normal AFP levels at diagnosis, and 
only 19% had AFP levels >200 ng/mL. Because accuracy 
of ultrasound is dependent on operator skill and experi- 
ence,27 more sensitive serum markers for HCC are needed 
to improve the results of HCC surveillance programs. 
Preliminary results of an ongoing study in our center 
found that des- y carboxy prothrombin is a more sensitive 
marker in the detection of HCC than AFP.2x 
In summary, we have reported the first large case series 
of HCC patients in the United States. We  found that, in 
addition to HCV, NAFLD is a common underlying liver 
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disease in American patients with HCC.  Prospective 
studies in patients with NASH will help determine the 
true incidence of HCC in this population. Because of the 
increasing prevalence of NAFLD, the incidence of HCC 
in the United States may continue to increase even after 
the consequences of the HCV epidemic have leveled off. 
Patients who underwent surveillance had smaller tumors 
at diagnosis and were more likely to be candidates for 
surgical or local ablative therapies. Although the 2 groups 
of patients in our series were not randomized, our findings 
suggest that surveillance of patients with cirrhosis can 
detect HCC at an earlier stage, possibly leading to an 
improved survival. Because of the low sensitivity of AFP, 
more reliable serum markers for HCC are needed to im- 
prove the results of surveillance programs. 
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